Blume Capital Management Inc. Sells 330 Shares of iShares Nasdaq Biotechnology ETF (IBB)

Blume Capital Management Inc. lowered its position in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 0.5% in the first quarter, Holdings Channel reports. The institutional investor owned 65,163 shares of the financial services provider’s stock after selling 330 shares during the quarter. iShares Nasdaq Biotechnology ETF comprises approximately 3.8% of Blume Capital Management Inc.’s holdings, making the stock its 6th largest position. Blume Capital Management Inc.’s holdings in iShares Nasdaq Biotechnology ETF were worth $7,285,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in IBB. Ellis Investment Partners LLC boosted its position in shares of iShares Nasdaq Biotechnology ETF by 10,590.0% during the 1st quarter. Ellis Investment Partners LLC now owns 1,761,815 shares of the financial services provider’s stock worth $1,761,000 after purchasing an additional 1,745,334 shares during the period. Deutsche Bank AG boosted its position in shares of iShares Nasdaq Biotechnology ETF by 32,925.6% during the 4th quarter. Deutsche Bank AG now owns 1,683,314 shares of the financial services provider’s stock worth $162,320,000 after purchasing an additional 1,678,217 shares during the period. State of Tennessee Treasury Department purchased a new position in shares of iShares Nasdaq Biotechnology ETF during the 4th quarter worth approximately $40,732,000. Lockheed Martin Investment Management Co. boosted its position in shares of iShares Nasdaq Biotechnology ETF by 173.9% during the 4th quarter. Lockheed Martin Investment Management Co. now owns 417,400 shares of the financial services provider’s stock worth $40,250,000 after purchasing an additional 265,000 shares during the period. Finally, Main Management LLC boosted its position in shares of iShares Nasdaq Biotechnology ETF by 14.2% during the 4th quarter. Main Management LLC now owns 398,987 shares of the financial services provider’s stock worth $38,474,000 after purchasing an additional 49,514 shares during the period. Institutional investors and hedge funds own 65.30% of the company’s stock.

NASDAQ:IBB opened at $101.30 on Tuesday. iShares Nasdaq Biotechnology ETF has a fifty-two week low of $89.01 and a fifty-two week high of $122.97.

COPYRIGHT VIOLATION WARNING: “Blume Capital Management Inc. Sells 330 Shares of iShares Nasdaq Biotechnology ETF (IBB)” was first published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/05/14/blume-capital-management-inc-sells-330-shares-of-ishares-nasdaq-biotechnology-etf-ibb.html.

About iShares Nasdaq Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Story: Fundamental Analysis

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.